Compare Enbridge Inc (ENB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Recursion Pharmaceuticals Inc — how do they compare? Enbridge Inc trades at $48.6 (market cap $109.79B), while Recursion Pharmaceuticals Inc trades at $3.77 (market cap $2.31B). The key difference: Enbridge Inc is far larger — about 47.5× Recursion Pharmaceuticals Inc's market cap, and Enbridge Inc pays a 5.69% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 93 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| ENB | RXRX | |
|---|---|---|
Market Cap | $109.79B | $2.31B |
Volume | 3,584,246 | 22,569,716 |
Sector | Energy | Health |
52-Week High | $58.04 | $5.00 |
52-Week Low | $45.23 | $2.84 |
Typical Hold Time | 93 Days | 22 Days |
Enterprise Value | $193.48B | $1.83B |
Dividend Yield | 5.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $49.2, down 0.53% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $61.63 implying significant upside. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a solid 6% dividend yield. Revenue grew to $65.19B in 2025, though net income margin dipped to 7.34%.
Outlook is positive with analyst support, but risks include high debt levels and sensitivity to interest rates. The stock offers value through dividends and growth potential, yet investors should monitor execution on its $41B project backlog and energy market volatility.
RXRX trades at $3.83, down 4.96% in the last session, with a bullish technical signal despite negative earnings. The company shows significant revenue growth challenges with a -961.97% net income margin, though recent partnerships and AI drug discovery platform developments provide potential catalysts. Analyst consensus is mixed with 40% buy ratings amid ongoing operational losses.
Investment outlook remains speculative given deep losses and high cash burn, offset by strategic partnerships with Tempus and Roche that could drive long-term value. Key risks include prolonged unprofitability and competitive pressures in AI-driven pharma, while technical indicators suggest near-term support near $3.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
